{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang C"],"funding":["National Natural Science Foundation of China"],"pagination":["1069-1078"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11971060"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["104(2)"],"pubmed_abstract":["The aim of this study was to investigate the prognostic value of baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated with P-GEMOX regimen (pegaspargase, gemcitabine and oxaliplatin). A total of 97 patients were retrospectively evaluated. The relationships between baseline PETCT metabolic parameters and survival were tested using Cox regression analysis and receiver operating characteristic(ROC) curve analysis was employed to evaluate the optimal cut-off value of these parameters. Kaplan-Meier curves with log-rank tests were used for survival analysis. At a median follow-up of 49 months, the 3-year PFS and OS were 62.9% and 70.1%. SUVmean, SUVmax, and SUVpeak were related to both PFS and OS in univariate "],"journal":["Annals of hematology"],"pubmed_title":["Metabolic parameter of baseline 18 F-FDG PET/CT with PINK models improve the prediction of treatment outcome in extranodal NK/T-cell lymphoma treated with P-GEMOX chemotherapy."],"pmcid":["PMC11971060"],"funding_grant_id":["82170188"],"pubmed_authors":["Ping L","Huang C","Li Y","Bai S","Bai B","He Y","He H","Zhang X","Huang H","Gao Y","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"Metabolic parameter of baseline 18 F-FDG PET/CT with PINK models improve the prediction of treatment outcome in extranodal NK/T-cell lymphoma treated with P-GEMOX chemotherapy.","description":"The aim of this study was to investigate the prognostic value of baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated with P-GEMOX regimen (pegaspargase, gemcitabine and oxaliplatin). A total of 97 patients were retrospectively evaluated. The relationships between baseline PETCT metabolic parameters and survival were tested using Cox regression analysis and receiver operating characteristic(ROC) curve analysis was employed to evaluate the optimal cut-off value of these parameters. Kaplan-Meier curves with log-rank tests were used for survival analysis. At a median follow-up of 49 months, the 3-year PFS and OS were 62.9% and 70.1%. SUVmean, SUVmax, and SUVpeak were related to both PFS and OS in univariate ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-07-08T03:13:38.776Z","creation":"2025-07-08T03:13:38.776Z"},"accession":"S-EPMC11971060","cross_references":{"pubmed":["39934426"],"doi":["10.1007/s00277-025-06243-y"]}}